The primary obstacle to effective nanomedicine is not necessarily the design of the drug itself, but the body’s highly efficient waste-disposal system. When therapeutic nanoparticles, liposomes, or gene vectors enter the bloodstream, they are immediately treated as foreign debris. This recognition triggers a process of sequestration by the mononuclear phagocyte system (MPS)—also known as the reticuloendothelial system (RES)—which filters these agents out of circulation and traps them in the liver and spleen.
The Biological Filter Problem
The MPS acts as a biological sieve. Specialized macrophages, particularly Kupffer cells in the liver, identify and ingest foreign particles within minutes of injection. As Pingping Feng et al. describe, this rapid sequestration prevents nanomedicines from maintaining the circulation time necessary to accumulate at target sites.
This clearance mechanism creates a paradox for drug delivery: to reach a tumor or an inflamed organ, a nanoparticle must stay in the blood long enough to find its target, yet the very act of being in the blood exposes it to the MPS. Yin Zhang et al. note that this premature clearance significantly reduces the concentration of diagnostic probes at intended pathological sites, limiting the window for accurate imaging. Furthermore, Min Zhang et al. highlight that repeated administration can trigger "accelerated blood clearance," where the immune system becomes even more efficient at removing subsequent doses, even when particles are coated with protective polymers like PEG.
Distracting the Cellular Cleanup Crew
One emerging strategy to bypass this filter is the use of "decoy" particles to temporarily saturate the MPS. By injecting a high dose of empty, harmless liposomes—a "Blocker"—researchers can distract the liver's macrophages. Pingping Feng et al. demonstrated that this saturation approach can extend the circulation time of subsequent nanomedicines by over two-fold.
This "Engage and Evasion" strategy, as framed by Hongman Liu et al., works by overwhelming the phagocytic capacity of the liver. While the macrophages are busy processing the decoy, the actual therapeutic agent—such as an extracellular vesicle—can slip past the filter and reach ischemic tissues in the heart or limbs.
Biomimetic Cloaking and Hitchhiking
Rather than just distracting the immune system, other researchers aim to hide from it entirely by mimicking the body's own cells. This "biomimetic" approach leverages the natural "self" signals that prevent the MPS from attacking healthy blood cells.
- Cell Membrane Encapsulation: By coating synthetic particles in membranes derived from leukemia cells or other host cells, researchers create "artificial cell vesicles." Xiaodong Zhuang et al. show that these cloaked vesicles enhance drug stability and targeting precision by evading the RES.
- RBC Hitchhiking: Red blood cells (RBCs) are natural long-circulators. Sheng Li et al. developed a system where nanoparticles adsorb onto the surface of RBCs. This allows the particles to "hitchhike" through the circulatory system, bypassing the MPS and eventually reaching lymphoid tissues to trigger a more potent immune response.
- Cellular Trojan Horses: Chun Zhang et al. argue for using living cells as carriers. Because the MPS does not typically clear healthy migratory cells, these "Trojan horses" can transport nanoparticles directly to disease sites that are otherwise shielded by biological barriers.
The Limits of Active Targeting
A common misconception in nanomedicine is that adding a targeting ligand (like an antibody or peptide) is sufficient to ensure delivery. However, Yuling Xiao et al. emphasize that the effectiveness of active targeting is strictly dependent on circulation half-life. If a particle is cleared by the liver in five minutes, it never has the chance to encounter the specific receptors on a tumor cell.
This is why researchers are moving toward multi-stage systems. For example, Astrid Gasselhuber et al. used mathematical modeling to show that temperature-sensitive liposomes, which release their payload only when triggered by local heat, can achieve much higher intracellular concentrations than standard "stealth" liposomes. By combining evasion (to stay in circulation) with triggered release (to ensure the drug enters the cell), these systems overcome the sequestration that hampers conventional chemotherapy.
Implications for Diverse Pathologies
The challenge of MPS clearance is universal across nanotherapeutic applications. In the treatment of Nonalcoholic Fatty Liver Disease, Bingyuan Fei et al. found that MPS clearance prevents anti-fibrotic agents from reaching the specific site of injury. Similarly, in preeclampsia research, Xiaojuan Zhang et al. noted that maternal liver sequestration limits the amount of gene-regulating siRNA that can reach the placenta. Across these fields, the consensus is clear: the success of nanomedicine depends less on the "payload" and more on the ability to navigate the body's complex system of biological filters.
Key Foundational Work
Multimodality Imaging of Integrin αvβ3 Expression (2011) — contributed 2 concept elements to this direction.
Gold Nanorods Conjugated with Doxorubicin and cRGD for Combined Anticancer Drug Delivery and PET Imaging (2012) — contributed 1 concept elements to this direction.
Comparison of Conventional Chemotherapy, Stealth Liposomes and Temperature-Sensitive Liposomes in a Mathematical Model (2012) — contributed 1 concept elements to this direction.